Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: GlaxoSmithKline vs. Pfizer

TheMotleyFool

0 0

Have all of the stocks of drugmakers in the coronavirus vaccine race delivered solid gains so far this year? Nope. GlaxoSmithKline's (NYSE: GSK) adjuvant is being used in three clinical-stage COVID-19 vaccine candidates, but its shares have plunged 20% year to date. Pfizer (NYSE: PFE) is arguably the clear leader in the race, but its shares are down around 7%.

The reason behind these declines is that both GlaxoSmithKline and Pfizer have a lot more going on than just their COVID-19 programs. Which of these stocks is the better choice for big-picture investors? Here's how GlaxoSmithKline and Pfizer compare on four key fronts.

Image source: Getty Images.

Source Fool.com

Like: 0

PFE

Share